Share on StockTwits

Cambrex (NYSE:CBM) SVP William M. Haskel sold 9,400 shares of Cambrex stock on the open market in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $21.94, for a total value of $206,236.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Cambrex (NYSE:CBM) traded down 0.05% during mid-day trading on Wednesday, hitting $22.06. The stock had a trading volume of 332,501 shares. Cambrex has a one year low of $12.56 and a one year high of $23.88. The stock has a 50-day moving average of $21.60 and a 200-day moving average of $20.68. The company has a market cap of $676.8 million and a price-to-earnings ratio of 20.70.

Cambrex (NYSE:CBM) last announced its earnings results on Tuesday, August 12th. The company reported $0.32 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.21 by $0.11. On average, analysts predict that Cambrex will post $1.08 earnings per share for the current fiscal year.

A number of research firms have recently commented on CBM. Analysts at Zacks upgraded shares of Cambrex from a “neutral” rating to an “outperform” rating in a research note on Monday, August 11th. They now have a $23.20 price target on the stock. Separately, analysts at First Analysis downgraded shares of Cambrex from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 8th. Finally, analysts at Longbow Research raised their price target on shares of Cambrex to $27.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock.

Cambrex Corporation (NYSE:CBM) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.

Receive News & Ratings for Cambrex Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co and related companies with Analyst Ratings Network's FREE daily email newsletter.